2 papers
stat.ME2022
Point estimation for adaptive trial designs II: practical considerations and guidance
David S. Robertson, Babak Choodari-Oskooei, Munya Dimairo +3
In adaptive clinical trials, the conventional end-of-trial point estimate of a treatment effect is prone to bias, that is, a systematic tendency to deviate from its true value. As…
stat.ME2021
Point estimation for adaptive trial designs I: a methodological review
David S. Robertson, Babak Choodari-Oskooei, Munya Dimairo +3
Recent FDA guidance on adaptive clinical trial designs defines bias as "a systematic tendency for the estimate of treatment effect to deviate from its true value", and states that…